Vivere Oncotherapies

Based in the US, Vivere Oncotherapies, Inc. is focused on developing innovative cancer therapies that harness the immune system to effectively target and eliminate tumors, especially those that are resistant to conventional treatments. Vivere Oncotherapies, Inc. specializes in advancing cancer treatment through immunotherapy.

Founded in 2022 and headquartered in Berkeley, California, the company has secured its first funding round, raising USD 10. 000 mn from diverse investors including Berkeley Frontier Fund, Freeflow Ventures, National Cancer Institute, Pillar, and YK Bioventures. This funding is intended to enhance the development of targeted immunotherapy treatments for cancer. The founder's previous entrepreneurial ventures are not publicly detailed.

Vivere Oncotherapies specializes in the development of next-generation cancer therapies that aim to activate the immune system to target and eliminate cancer cells, particularly in cold tumors that evade detection by the body’s natural defenses. The company's core offerings center around a proprietary bioengineering platform that enhances the delivery and efficacy of treatments, enabling them to breach the immunological tolerance of tumors. This platform is underpinned by over 25 years of research and is designed to provide innovative solutions in oncology, addressing challenging cancers with few effective treatments available. The company primarily serves a client base comprising hospitals, oncology clinics, and research institutions in North America and Europe, focusing on advanced cancer therapies that require targeted, safe, and effective intervention.

Vivere Oncotherapies operates within a B2B model, engaging in partnerships with healthcare providers and research institutions to facilitate the development and deployment of its therapies. Revenue generation occurs through collaborative agreements and potential licensing deals, where partners may invest in the development process in exchange for access to the therapies and technology. The company may structure transactions based on milestones in research and development, leading to staged investments as specific therapeutic targets are achieved. Additionally, pricing structures may include upfront fees for access to the proprietary platform, milestone payments as progress is made, and royalties on future sales of therapies once they reach the market.

Specific pricing details or financial arrangements for products and services are proprietary and not disclosed. Vivere Oncotherapies plans to utilize its recent funding of USD 10. 000 mn raised in January 2026 to advance the development of targeted immunotherapy treatments for cancer. As part of its growth strategy, the company aims to expand its presence in both North America and Europe, focusing on markets where advanced cancer therapies are in high demand.

The strategic deployment of these funds is expected to support the introduction of new products designed to tackle challenging cancers, with specific timelines and detailed product launches to be outlined as development progresses.